DEXTROSE INJECTION SOLUTION

Country: Kanada

Bahasa: Inggeris

Sumber: Health Canada

Bahan aktif:

DEXTROSE

Boleh didapati daripada:

OMEGA LABORATORIES LIMITED

Kod ATC:

B05BA03

INN (Nama Antarabangsa):

CARBOHYDRATES

Dos:

50%

Borang farmaseutikal:

SOLUTION

Komposisi:

DEXTROSE 50%

Laluan pentadbiran:

INTRAVENOUS

Unit dalam pakej:

15G/50G

Jenis preskripsi:

Ethical

Kawasan terapeutik:

CALORIC AGENTS

Ringkasan produk:

Active ingredient group (AIG) number: 0102181001; AHFS:

Status kebenaran:

APPROVED

Tarikh kebenaran:

2021-06-15

Ciri produk

PRESCRIBING INFORMATION
DEXTROSE INJECTION
50% W / V
(500 mg / mL)
Concentrated Dextrose for Intravenous Administration
USP STANDARD
Fluid and Nutrient Replenisher
Omega Laboratories Limited DATE OF PREPARATION:
11 177 Hamon
June 15, 2021
Montreal, Quebec
Canada, H3M 3E4
SUBMISSION CONTROL NO: 232989
DEXTROSE INJECTION
50% W / V
(500 mg / mL)
NOTE: This solution is hypertonic - see WARNINGS and PRECAUTIONS
ACTION AND CLINICAL PHARMACOLOGY
When administered intravenously this solution restores blood glucose
levels in hypoglycemia and
provides a source of carbohydrate calories.
Carbohydrate in the form of dextrose may aid in minimizing liver or
glycogen depletion and exerts a
protein-sparing action. Dextrose injection undergoes oxidation to
carbon dioxide and water.
INDICATIONS AND CLINICAL USE
Dextrose Injection is indicated in the treatment of insulin
hypoglycemia (hyperinsulinism or insulin
shock) to restore blood glucose levels.
The solution is also indicated after dilution, for intravenous
infusion as a source of carbohydrate calories
in patients whose oral intake is restricted or inadequate to maintain
nutritional requirements. Slow
infusion of hypertonic solutions is essential to insure proper
utilization of dextrose and avoid production
of hyperglycemia.
CONTRAINDICATIONS
A concentrated dextrose solution should not be used when intracranial
or intraspinal hemorrhage is
present, nor in the presence of delirium tremens if the patient is
already dehydrated.
Dextrose injection without electrolytes should not be administered
simultaneously with blood through the
same infusion set because of the possibility that pseudo-agglutination
of red cells may occur.
WARNINGS
Dextrose Injection is hypertonic and may cause phlebitis and
thrombosis at the site of injection.
Significant hyperglycemia and possible hyperosmolar syndrome may
result from a too rapid
administration. The physician should be aware of the symptoms of
hyper-osmolar syndrome, such as
mental confusion and loss of consciousness, especially in patients
wit